Categories Earnings, Other Industries

Strong product demand boosts Grainger’s first quarter results

Grainger (GWW) reported better-than-expected first quarter results, primarily due to strong demand and better volumes in its US business. The company’s adjusted earnings rose 45% to $4.18 per share, beating street estimates. Sales for the quarter came in at $2.8 billion, up 9% compared to the prior-year period due to improved volumes. Operating margins improved 60 basis points to 12.1%.

Sales in the US segment rose 8% to $2.1 billion. Meanwhile, the Canadian business posted $20 million in operating loss due to declining sales and ongoing restructuring efforts. Other Businesses sales increased 18% compared to last year, primarily due to a 24% sales growth from its online business. The company expects the growth trend to continue from its online business, which would augur well to its bottom-line.

Branch closures continued in the first quarter. Total branches at the end of the first quarter stood at 480 compared to 500 at the end of last quarter. As expected, most of the closures (17 branches) were in Canada. The company ended the first quarter with 32 distribution centers.

Grainger is upbeat about the full-year results due to the improving volumes and strong demand for its products, besides the ongoing transformation efforts in the Canadian business.

The company has raised its sales and earnings forecast for 2018. It now expects sales growth of 5% to 8%, compared to 3% to 7% reported last quarter. Earnings are predicted to be between $14.30 and $15.30 per share vs $12.95 to $14.15 reported in the fourth quarter.

Grainger’s price reduction strategy to tackle competition from Amazon and its peers seem to be bearing fruit. On top of that, the company has reported volume growth due to strong demand in the Industrial sector for the past two quarters. Grainger’s share price has increased 29% in 2018, exceeding the 16% growth recorded by the US Industrial Index.

Grainger First Quarter 2018 Earnings

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Tags

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top